Literature DB >> 30580931

Outcomes of revision anterior cruciate ligament reconstruction secondary to reamer-irrigator-aspirator harvested bone grafting.

W C Prall1, T Kusmenkov2, J Fürmetz2, F Haasters3, H O Mayr4, W Böcker2, S Grote5.   

Abstract

INTRODUCTION: Patients with widened or misplaced tunnels may require bone grafting prior to revision anterior cruciate ligament (ACL) reconstruction. Utilising reamer-irrigator-aspirator (RIA) harvested bone from the femur showed promising filling rates. Nevertheless, the procedure has neither been validated in a larger population nor been assessed with regards to radiological and clinical outcome of the subsequently conducted revision ACL reconstruction. Therefore, the aim of this study was to evaluate tunnel filling rates, positioning of the revision tunnels and outcome parameters of such two-staged revision ACL reconstructions.
MATERIAL AND METHODS: A total of 15 consecutive patients were prospectively enrolled in this case series. CT scans were analysed before and after autologous RIA harvested bone grafting. Tunnel volumes and filling rates were calculated based on manual segmentation of axial CT scans. Revision ACL reconstruction was carried out after a mean interval of 6.2 months (±3.7) and positioning of the revision tunnels was assessed by plane radiographs. The mean follow-up was 19.8 months (±8.4) for objective evaluation and 37.1 months (±15.4) for patient reported outcomes. The clinical outcome was assessed by the quantification of the anterior tibial translation, the IKDC objective score, the Tegner activity scale and the Lysholm score.
RESULTS: Initial CT scans revealed mean tunnel volumes of 3.8cm3 (±2.7) femoral and 6.1cm3 (±2.4) tibial. Filling rates of 76.1% (±12.4) femoral and 87.4% (±5.9) tibial were achieved. Postoperative radiographs revealed significantly improved tunnel positioning with anatomical placement in all but one case at the femur and in all cases at the tibia. At follow up, patients showed significantly improved anterior tibial translations with residual side-to-side differences of 1.7 mm (±0.8) and significantly improved IKDC objective scores. Furthermore, significantly higher values were achieved on the Tegner activity scale (5.3 ± 1.4 vs. 2.8 ± 0.5) and the Lysholm score (85.4 ± 7.9 vs. 62.5 ± 10.5) compared to the preoperative status.
CONCLUSION: Autologous RIA harvested bone grafting ensures sufficient bone stock consolidation allowing for anatomical tunnel placement of the subsequently conducted revision ACL reconstruction. The two-staged procedure reliably restores stability and provides satisfying subjective and objective outcomes. Thus, RIA harvested bone grafting is an eligible alternative to autologous iliac crest or allogenic bone grafting.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anterior cruciate ligament; Bone grafting; Outcome; RIA; Reamer-irrigator-aspirator; Revision ACL reconstruction; Tunnel positioning; Two-staged

Mesh:

Year:  2018        PMID: 30580931     DOI: 10.1016/j.injury.2018.12.020

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

1.  Arthroscopic Harvesting of Autologous Bone Graft for Use as a Mesenchymal Stem Cell Carrier in Anterior Cruciate Ligament Reconstruction.

Authors:  Angelica Marie van Gogh; Xingguang Li; Gun Min Youn; Alyssa Alvarez; Sophia Yin; Moyukh O Chakrabarti; Patrick J McGahan; James L Chen
Journal:  Arthrosc Tech       Date:  2019-12-18

2.  Bone Grafting Technique in Revision ACL Reconstruction: Coring Reamer and Dowel Trick.

Authors:  Nels D Leafblad; Travis G Maak
Journal:  Arthrosc Tech       Date:  2022-06-21

3.  Cancellous allogenic and autologous bone grafting ensure comparable tunnel filling results in two-staged revision ACL surgery.

Authors:  Wolf Christian Prall; T Kusmenkov; B Schmidt; J Fürmetz; F Haasters; J H Naendrup; W Böcker; S Shafizadeh; H O Mayr; T R Pfeiffer
Journal:  Arch Orthop Trauma Surg       Date:  2020-04-01       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.